This is a scientific update with no immediate stock-moving catalyst. Monitor for future clinical trial results (Acclaim-1, -2, -3) and any biomarker-driven patient selection strategy updates. The tiny patient sample (n=18) limits statistical power.
Price Chart
Executive Summary
Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Meeting, detailing positive clinical data on predictive biomarkers (Trop-2 and PTEN) for its lead drug candidate Reqorsa Gene Therapy in lung cancer. The data from 18 patients showed that high Trop-2 and low PTEN levels correlated with prolonged progression-free survival in NSCLC, but not in SCLC. This is an early-stage scientific update with no financial data or near-term catalyst.
Key Facts
- Abstract published at 2026 ASCO Annual Meeting titled 'Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid'
- Data from 18 patients across three Acclaim clinical trials (Acclaim-1, Acclaim-2, Acclaim-3)
- In NSCLC patients (n=7), Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05) and PTEN H-scores below 100 correlated with prolonged PFS (p=0.03)
- In SCLC patients (n=11), Trop-2 H-scores were universally low and non-evaluable; PTEN did not correlate with PFS (p=0.53)
- High (3+) Trop-2 expression will be investigated further as a potential biomarker for REQORSA
- No financial figures, guidance, or regulatory milestones disclosed
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage biotech with $7M market cap
Risk Factors
- Very small sample size (18 patients) limits reliability of biomarker correlations
- Biomarker findings are exploratory and require validation in larger trials
- No timeline for next clinical data readout or regulatory submission
- Company faces going concern risk per forward-looking statements in filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018318 |
| Document: 0001437749-26-018318-index-headers.html | 0001437749-26-018318 |
| Document: 0001437749-26-018318-index.html | 0001437749-26-018318 |
| Document: 0001437749-26-018318.txt | 0001437749-26-018318 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.05 | awaiting T+60 | — | $1.81 (−11.71%) |
Aug 18, 2026 9w ago | 8-K | $3.95 | awaiting T+60 | — | $1.81 (−54.18%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.81 (−61.89%) |
Jul 14, 2026 14w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.81 (−290.76%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.81 (+229.03%) |
May 26, 2026 21w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.81 (−89.34%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.81 (−90.44%) |
Apr 28, 2026 25w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.81 (−91.11%) |
Apr 21, 2026 26w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.81 (−92.45%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.81 (−9.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers